Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2001
10/30/2001US6309645 A method of suppressing an immune response in a mammal.
10/30/2001US6309638 Netrins
10/30/2001US6309634 Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)
10/30/2001CA2048931C Carbamoyl-1-(pyridinylalkyl)-1h-indoles, indolines and related analogs
10/30/2001CA2048027C 3-arylindole and 3-arylindazole derivatives
10/25/2001WO2001083485A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001WO2001079525A2 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
10/25/2001WO2001079498A2 16051a and 16051b, novel human pdz family members and uses thereof
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079455A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN
10/25/2001WO2001079448A2 Trp8, a transient receptor potential channel expressed in taste receptor cells
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079298A1 Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same
10/25/2001WO2001079291A2 Secreted proteins
10/25/2001WO2001079283A1 Modulating cell survival by modulating huntingtin function
10/25/2001WO2001079282A2 Molecules associated with human reproduction
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079263A1 Peptide derivatives and medicinal compositions
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079256A1 19-norbufalin derivatives, their preparation and pharmaceutical compositions containing them
10/25/2001WO2001079244A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
10/25/2001WO2001079206A1 Tricyclic quinazolinediones
10/25/2001WO2001079197A1 ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
10/25/2001WO2001079185A1 Novel amino carboxy alkyl derivatives of barbituric acid
10/25/2001WO2001079184A1 Substituted piperazine compounds
10/25/2001WO2001079177A1 Cyclic diaza compounds for treating neurodegenerative disorders
10/25/2001WO2001079173A2 Enamine derivatives as cell adhesion molecules
10/25/2001WO2001079170A2 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/25/2001WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001079153A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
10/25/2001WO2001078789A2 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001WO2001078768A2 Targeted vaccine delivery systems
10/25/2001WO2001078760A2 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001WO2001078757A2 Reversible immortalization
10/25/2001WO2001078755A2 A novel polypeptide - human ataxia-telangiectasia mutant protein 9 and a polynucleotide encoding the same
10/25/2001WO2001078754A2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
10/25/2001WO2001078753A2 Therapeutic uses for mesenchymal stromal cells
10/25/2001WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate
10/25/2001WO2001078733A1 Alpha,beta-unsaturated sulfones for treating proliferative disorders
10/25/2001WO2001078728A1 Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts
10/25/2001WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2
10/25/2001WO2001078722A1 Pharmaceutical compositions containing 5-hydroxyoxindole and use thereof
10/25/2001WO2001078721A1 Aβ42 LOWERING AGENTS
10/25/2001WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078718A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage
10/25/2001WO2001078713A1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
10/25/2001WO2001078712A1 Substituted styryl benzylsulfones for treating proliferative disorders
10/25/2001WO2001078711A2 Pde-v inhibitors for treatment of parkinson's disease
10/25/2001WO2001078709A2 Treatment of neurodegenerative disease
10/25/2001WO2001078703A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001WO2001078688A1 Hydrophilic/lipophilic polymeric matrix dosage formulation
10/25/2001WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078649A2 Pharmaceutical curative compound
10/25/2001WO2001078580A2 A method combining inducing hypothermia and administering a therapeutic agent
10/25/2001WO2001078530A2 Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
10/25/2001WO2001051064A8 Ph-regulators against oral stereotypies in equines
10/25/2001WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001WO2001040499A3 Methods for cell screening of compounds capable of modulating the activity of ubiquitin-ligase scf complexes and their uses
10/25/2001WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001WO2001023570A3 Methods and compositions relating to sodium channel beta-1a subunits
10/25/2001WO2001021605A3 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2000061541A8 Pharmaceutical compounds
10/25/2001WO2000047618A9 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
10/25/2001WO2000011169A3 Human cell signaling proteins (csig)
10/25/2001US20010034884 Abeta-peptide screening assay
10/25/2001US20010034451 Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders
10/25/2001US20010034444 Treating schizophrenia, depression, and Parkinson's disease; side effect reduction
10/25/2001US20010034370 Carnosic acid derivatives for promoting synthesis of nerve growth factor
10/25/2001US20010034362 Pyrrolidine derivatives for vision and memory disorders
10/25/2001US20010034359 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
10/25/2001US20010034357 Substituted pyridine compounds useful for controlling chemical synaptic transmission
10/25/2001US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001US20010034347 A pyrido(1,2-a)pyrazine compound
10/25/2001US20010034345 Administering a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
10/25/2001US20010034340 Hormone replacement therapy
10/25/2001US20010034337 Antiproliferative agents
10/25/2001US20010034331 Isolated polypeptide
10/25/2001US20010034051 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
10/25/2001US20010034035 Amino acid sequences derived partially from ependymin that binds with calcium; stroke and other neurodegenerative diseases; antiischemic agents; cognition activators; conjugated to transfer through blood-brain barrier
10/25/2001US20010033866 Sustained release oral formulations
10/25/2001US20010033858 Sustained release
10/25/2001US20010033834 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
10/25/2001DE10019195A1 Gene complex for reversible cell immortalization, useful for expanding cells for cell replacement therapy of e.g. neurodegenerative disease, contains removable immortalizing gene
10/25/2001DE10019062A1 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
10/25/2001DE10018834A1 Transdermal or transmucosal pharmaceutical dosage form for treatment of nicotine dependence or smoking withdrawal contains nicotine compound or substitute and CNS active compound
10/25/2001CA2747325A1 Albumin fusion proteins
10/25/2001CA2485920A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001CA2485919A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001CA2409190A1 Poliovirus replicons encoding therapeutic agents and uses thereof
10/25/2001CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001CA2407031A1 Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
10/25/2001CA2406481A1 Trp8, a transient receptor potential channel expressed in taste receptor cells
10/25/2001CA2406383A1 A.beta.42 lowering agents
10/25/2001CA2406378A1 Targeted vaccine delivery systems
1 ... 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 ... 1833